Tislelizumab has previously demonstrated a high complete response rate regardless of FcγRΙ-expressing Mφ abundance in the classical Hodgkin lymphoma TME [41, 42], further supporting the lack of a negative effect of CD64+ Mφ infiltration on the anti-tumor activity of tislelizumab. This evidence concerns the gene FCGR1A and neoplasm.